Der Nephrologe

, Volume 8, Issue 4, pp 298–307 | Cite as

Kardiorenales Syndrom

Leitthema
First Online:
  • 574 Downloads

Zusammenfassung

Das kardiorenale Syndrom gliedert sich entsprechend dem führenden Schädigungsmechanismus (Niereninsuffizienz oder Herzinsuffizienz) in verschiedene Formen auf. Pathophysiologisch sind vor allem hämodynamische Faktoren, neurohumorale Mechanismen, die endotheliale Dysfunktion sowie inflammatorische Prozesse an der Entwicklung eines kardiorenalen/renokardialen Syndroms beteiligt. Therapeutisch stehen daher die Regulierung des Volumenhaushalts, die Blockade des RAAS und die Behandlung der eine Niereninsuffizienz begleitenden Probleme im Vordergrund. Zukünftig muss die Wichtigkeit der verschiedenen pathophysiologischen Faktoren und der damit zusammenhängenden therapeutischen Strategien vor dem Hintergrund der unterschiedlichen Formen des kardiorenalen Syndroms weiter untersucht werden.

Schlüsselwörter

Renokardiales Syndrom Herzinsuffizienz Niereninsuffizienz Pathophysiologie Therapie 

Cardiorenal syndrome

Abstract

During recent years it has become evident that renal failure can promote heart failure and vice versa. Thus, the term cardiorenal syndrome was coined involving hemodynamic factors, neurohumoral mechanisms, inflammatory processes and endothelial dysfunction as pathophysiological pathways. Therapeutic goals include correction of the volume status and hemodynamic parameters, blockade of the renin-angiotensin-aldosterone system (RAAS) as well as control of concomitant comorbidities. Future studies should aim at the importance of the various pathophysiological factors together with the corresponding therapeutic strategies and precise epidemiological information in these patients.

Keywords

Cardiorenal syndrome Heart failure Renal insufficiency Pathophysiology Therapy 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Ronco C, Haapio M, House AA et al (2008) Cardiorenal syndrome. J Am Coll Cardiol 52(19):1527–1539PubMedCrossRefGoogle Scholar
  2. 2.
    Maeder MT, Holst DP, Kaye DM (2008) Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J Card Fail 14(10):824–830PubMedCrossRefGoogle Scholar
  3. 3.
    Ronco C, Cicoira M, McCullough PA (2012) Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60(12):1031–1042PubMedCrossRefGoogle Scholar
  4. 4.
    Burns WC, Thomas MC (2011) Angiotensin II and its role in tubular epithelial to mesenchymal transition associated with chronic kidney disease. Cells Tissues Organs 193(1–2):74–84Google Scholar
  5. 5.
    Münzel T, Sinning C, Post F et al (2008) Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 40(3):180–196PubMedCrossRefGoogle Scholar
  6. 6.
    Virzì GM, Torregrossa R, Cruz DN et al (2012) Cardiorenal syndrome type 1 may be immunologically mediated: a pilot evaluation of monocyte apoptosis. Cardiorenal Med 2(1):33–42PubMedCrossRefGoogle Scholar
  7. 7.
    Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32(9):2045–2051PubMedCrossRefGoogle Scholar
  8. 8.
    Remuzzi G, Perico N, Macia M, Ruggenenti P (2005) The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl (99):S57–S65CrossRefGoogle Scholar
  9. 9.
    Jaisser F, Swynghedauw B, Delcayre C (2011) The mineralocorticoid receptor in heart: different effects in different cells. Hypertension 57(4):679–680PubMedCrossRefGoogle Scholar
  10. 10.
    Libetta C, Sepe V, Esposito P et al (2011) Oxidative stress and inflammation: implications in uremia and hemodialysis. Clin Biochem 44(14–15):1189–1198Google Scholar
  11. 11.
    Jackson CE, Solomon SD, Gerstein HC et al; CHARM Investigators and Committees (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374(9689):543–550PubMedCrossRefGoogle Scholar
  12. 12.
    Cozzolino M, Ketteler M, Zehnder D (2010) The vitamin D system: a crosstalk between the heart and kidney. Eur J Heart Fail 12(10):1031–1041PubMedCrossRefGoogle Scholar
  13. 13.
    Park CW, Oh YS, Shin YS et al (1999) Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33(1):73–81PubMedCrossRefGoogle Scholar
  14. 14.
    Chen S, Law CS, Grigsby CL et al (2011) Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124(17):1838–1847PubMedCrossRefGoogle Scholar
  15. 15.
    Weiner DE, Tighiouart H, Vlagopoulos PT et al (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16(6):1803–1810PubMedCrossRefGoogle Scholar
  16. 16.
    Foley RN, Parfrey PS, Harnett JD et al (1996) The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28(1):53–61PubMedCrossRefGoogle Scholar
  17. 17.
    Hasselblad V, Gattis Stough W, Shah MR et al (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9(10):1064–1069PubMedCrossRefGoogle Scholar
  18. 18.
    Felker GM, Lee KL, Bull DA et al; NHLBI Heart Failure Clinical Research Network (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797–805PubMedCrossRefGoogle Scholar
  19. 19.
    Costanzo MR, Guglin ME, Saltzberg MT et al; UNLOAD Trial Investigators (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49(6):675–683PubMedCrossRefGoogle Scholar
  20. 20.
    Bart BA, Goldsmith SR, Lee KL et al; Heart Failure Clinical Research Network (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367(24):2296–2304PubMedCrossRefGoogle Scholar
  21. 21.
    Nakayama M, Nakano H, Nakayama M (2010) Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. J Cardiol 55(1):49–54PubMedCrossRefGoogle Scholar
  22. 22.
    Sánchez JE, Ortega T, Rodríguez C et al (2010) Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 25(2):605–610PubMedCrossRefGoogle Scholar
  23. 23.
    Koch M, Haastert B, Kohnle M et al (2012) Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail 14(5):530–539PubMedCrossRefGoogle Scholar
  24. 24.
    Swedberg K, Young JB, Anand IS et al; RED-HF Committees; RED-HF Investigators (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210–1219PubMedCrossRefGoogle Scholar
  25. 25.
    Ahmad M, Robert R, Bargman JM, Oreopoulos D (2008) Advantages of peritoneal dialysis in comparison to hemodialysis, in cardiac allograft recipients with end stage renal disease. Int Urol Nephrol 40(4):1083–1087PubMedCrossRefGoogle Scholar
  26. 26.
    Roob JM (2005) Comparison of clinical outcomes in peritoneal dialysis and hemodialysis. Wien Klin Wochenschr 117(Suppl 6):60–68PubMedCrossRefGoogle Scholar
  27. 27.
    Mann JF, Schmieder RE, McQueen M et al; ONTARGET Investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638):547–553PubMedCrossRefGoogle Scholar
  28. 28.
    Singh AK, Szczech L, Tang KL et al; CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085–2098PubMedCrossRefGoogle Scholar
  29. 29.
    Zeeuw D de, Agarwal R, Amdahl M et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376(9752):1543–1551PubMedCrossRefGoogle Scholar
  30. 30.
    Thadhani R, Appelbaum E, Pritchett Y et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307(7):674–684PubMedCrossRefGoogle Scholar
  31. 31.
    EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482–2494CrossRefGoogle Scholar
  32. 32.
    Bruck H (2012) Kardiorenales Syndrom – Pathophysiologie, Klassifikation und Epidemiologie; Nephrologie im Dialog. Springer, Heidelberg Berlin New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.I. Medizinische KlinikUniversitätsmedizin MainzMainzDeutschland
  2. 2.Klinik für NephrologieUniversitätsklinikum Essen, Universität Duisburg-EssenEssenDeutschland
  3. 3.II. Medizinische KlinikUniversitätsmedizin MainzMainzDeutschland

Personalised recommendations